From Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medicine, New York, New York.
J Natl Compr Canc Netw. 2017 Nov;15(11):1429-1437. doi: 10.6004/jnccn.2017.7045.
Adoptive T-cell therapy with chimeric antigen receptor T cells (CAR-Ts) has produced impressive clinical responses among patients with B-cell malignancies, and several groups have published positive results using anti-CD19 CAR-Ts for the treatment of B-cell acute lymphoblastic leukemia. Recently, new data from clinical trials have demonstrated the benefits of CAR-T therapy in the non-Hodgkin's lymphoma (NHL) setting. This review describes some of the most recent and promising advances in engineered T-cell therapy, with particular emphasis on the clinical benefits of NHL treatment.
嵌合抗原受体 T 细胞（CAR-T 细胞）过继细胞疗法在 B 细胞恶性肿瘤患者中产生了令人瞩目的临床反应，多个研究小组已经发表了使用抗 CD19 CAR-T 细胞治疗 B 细胞急性淋巴细胞白血病的积极结果。最近，临床试验的新数据表明 CAR-T 疗法在非霍奇金淋巴瘤（NHL）治疗中的益处。本文综述了工程 T 细胞疗法的一些最新和有前途的进展，特别强调了 NHL 治疗的临床获益。
J Natl Compr Canc Netw. 2017-11
Proc Natl Acad Sci U S A. 2016-1-26
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024-6
Hum Gene Ther. 2017-12
Leuk Lymphoma. 2018-8
Proc Natl Acad Sci U S A. 2016-1-26
Cancer Immunol Immunother. 2024-1-27
Vaccines (Basel). 2023-3-4
iScience. 2022-10-10
Cancers (Basel). 2021-5-26
Theranostics. 2018-11-10
Zotero 插件